• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Stop the resignations! Make salaries right!!!

Quote
anonymous said:
Man that district is down to a couple TMs and they got a new RSM. Lots of vacancies to fill there and nationwide. I’m glad I’m not on biologics. What a disaster.
Click to expand...

It’s tough on biologics. Every section of that division has had resignations on all levels. A relaunch is what Iluyma needs but a relaunch screams major problems within company.
 
























anonymous said:
Relaunches are never as successful as everyone thinks. This place is an epic fucking disaster. Remember for the TM’s that are still here aren’t working much at all.
Click to expand...

Wrong.
Relaunches are virtually never a success but rather a further drain on the company.
Many a data and case studies that show the product revenue/share lifecycle is set in the first six months. Almost never-ever does that trajectory change.
#piglipstick
#stillapig
 




anonymous said:
Wrong.
Relaunches are virtually never a success but rather a further drain on the company.
Many a data and case studies that show the product revenue/share lifecycle is set in the first six months. Almost never-ever does that trajectory change.
#piglipstick
#stillapig
Click to expand...

Correct. Relaunch spells failure to the customers and wall street about the organization and the product. 97% of proclaimed "relaunches" in pharmaceuticals (according to fierce pharma) result in less than a 10% increase from baseline. The argument was also made that it is a red flag to current users, and can be exponentially damaging.
 




anonymous said:
Correct. Relaunch spells failure to the customers and wall street about the organization and the product. 97% of proclaimed "relaunches" in pharmaceuticals (according to fierce pharma) result in less than a 10% increase from baseline. The argument was also made that it is a red flag to current users, and can be exponentially damaging.
Click to expand...

Fix the HUB and you have fixed 80% of the problem. You can gain share (call it re-launch or anything else) if access is up to standard. Bad coverage and a lousy HUB equals no improvement over current mediocre.
 








anonymous said:
Correct. Relaunch spells failure to the customers and wall street about the organization and the product. 97% of proclaimed "relaunches" in pharmaceuticals (according to fierce pharma) result in less than a 10% increase from baseline. The argument was also made that it is a red flag to current users, and can be exponentially damaging.
Click to expand...

If Merck were to re-launch Ilumya, then success might be possible.
 




















Top Bottom
Back
Quote